Endothelin receptor antagonists: Rationale, clinical development, and role in prostate cancer therapeutics

Current Oncology Reports

Volumn 8, Issue 2, 2006, Pages 108-113

  Thakkar, Snehal G ^b   Choueiri, Toni K ^b   Garcia, Jorge A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ATRASENTAN; BOSENTAN; CARBOXY TERMINAL TELOPEPTIDE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DEOXYPYRIDINOLINE; DOCETAXEL; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PLACEBO; PREDNISONE; ZOLEDRONIC ACID;

ANGIOGENESIS; APOPTOSIS; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOMA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; GENE TARGETING; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; MALE; MELANOMA; OVARY CARCINOMA; PERIPHERAL EDEMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; REVIEW; RHINITIS; UTERINE CERVIX CARCINOMA;

EID: 33645542495     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0045-1     Document Type: Review

References (50)

1. Levin ER: Endothelins. N Engl J Med 1995, 333:356-363.
2. Masaki T. The endothelin family: An overview. J Cardiovasc Pharmacol 2000, 35:S3-S5.
3. Goldie RG: Endothelins in health and disease: An overview. Clin Exp Pharmacol Physiol 1999, 26:145-148.
4. Bagnato A, Catt KJ: Endothelin as autocrine regulators of tumor cell growth. Trends Endocr Metab 1998, 9:378-383.
5. Nelson JB, Carducci MA: The role of the endothelin-1 and endothelin receptor antagonists in prostate cancer axis. BJU Int 2000, 85(Suppl 2):45-48.
6. Inoue A, Yanagisawa M, Kimura Y, et al.: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989, 86:2863-2867.
7. Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: Emerging role in cancer. Nat Rev Cancer 2003, 3:110-116.
8. Battistini B, Chailler P, D'Orleans-juste P, et al.: Growth regulatory properties of endothelins. Peptides 1993, 14:385-399.
9. Pristivishalil G, Nelson JB: Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000, 44:44-77.
10. Shichiri M, Kato H, Marumo F, Hirata Y. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 1997, 30:1198-1203.
11. Eberl LP, Egidy G, Pinet F, Juillerat-Jeanneret L: Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C pathway. J Cardiovasc Pharmacol 2000, 36:S354-S356.
12. Eberl LP, Valdenaire O, Saintgiorgio V, et al.: Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J 2000, Cancer 2000, 86:182-187.
13. Nelson JB, Hguyen SH, Wu-Wong JR, et al.: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999, 53:1063-1069.
14. Boyce BF, Yoneda T, Guise TA: Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999, 6:333-347.
15. Mundy GR: Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci U S A 2003, 100:10954-10969.
16. Salani D, Di Castro V, Nicotra MR, et al.: Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000, 157:1537-1547.
17. Bek EL, McMillen MA: Endothelins are angiogenic. J Cardiovasc Pharmacol 2000, 36:S135-S139.
18. Bagnato A, Salani D, Di Castro V, et al.: Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth. Cancer Res 1999, 59:720-727.
19. Salani D, Taraboletti G, Rosano L, et al.: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000, 157:1703-1711.
20. Spinella F, Rosano L, Di Castro V, et al.: Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor 1alpha in ovarian cancer cells. J Biol Chem 2002, 277:27850-27855.
21. Rosano L, Varmi M, Salani D, et al.: Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001, 61:8340-8346.
22. Rosano L, Salani D, Di Castro V, et al.: Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci 2002, 103:306S-309S.
23. Thevarajah S, Udan MS, Zheng H, et al.: Endothelin axis expression in renal cell carcinoma. J Urol 1999, 161:137.
24. Bagnato A, Tecce R, Moretti C, et al.: Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1995, 1:1059-1066.
25. Moraitis S, Langdon SP, Miller WR: Endothelin expression and responsiveness in human ovarian carcinoma cell lines. Eur J Cancer 1997, 33:661-668.
26. Gohji K, Kitazawa S, Tamada H, et al.: Expression of endothelin receptor A associated with prostate cancer progression. J Urol 2001, 165:1033-1036.
27. Yamashita J, Ogawa M, Inada K, et al.: A large amount of endothelin-1 is present in human breast cancer tissues. Res Commun Chem Pathol Pharmacol 1991, 74:363-369.
28. Alanen K, Deng DX, Chakrabarti S: Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology 2000, 36:161-167.
29. Asham E, Shankar A, Loizidou M, et al.: Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ETA receptor antagonism. Br J Cancer 2001, 85:1759-1763.
30. Egidy G, Juillerat-Jeanneret L, Jeannin JF, et al.: Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol 2000, 157:1863-1874.
31. Zhao YD, Xu LX, Chandler JW, et al.: Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors. J Cardiovasc Res 1995, 26:S341-S345.
32. Ahmed SI, Thompson J, Coulson JM, Woll PJ: Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 2000, 22:422-431.
33. Yohn JJ, Smith C, Stevens T, et al.: Human melanoma cells express functional endothelin-1 receptors. Biochem Biophys Res Commun 1994, 201:449-457.
34. Kikuchi K, Nakagawa H, Kadono T, et al.: Decreased ET(B) receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun 1996, 219:734-739.
35. Eberle J, Weitmann S, Thieck O, et al.: Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 1999, 112:925-932.
36. Demunter A, De Wolf-Peeters C, Degreef H, et al.: Expression of the endothelin-B receptor in pigment cell lesions of the skin: Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001, 438:485-491.
37. Nambi P, Wu HL, Lipshutz D, Prabhakar U: Identification and characterization of endothelin receptors on rat osteoblastic osteosarcoma cells: down-regulation by 1,25- dihydroxy-vitamin D3. Mol Pharmacol 1995, 47:266-271.
38. Grimshaw MJ, Naylor S, Balkwill FR: Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther 2002, 14:1273-1281.
39. Salani D, Rosano L, Di Castro V, et al.: ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in-vitro. Clin Sci 2002, 103:318S-321S.
40. Venuti A, Salani D, Manni V, et al.: Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: New potential targets for anticancer therapy. FASEB J 2000, 14:2277-2283.
41. Bagnato A, Cirilli A, Salani D, et al.: Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002, 62:6381-6384.
42. Papandreou CN, Usmani B, Geng Y, et al.: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen independent progression. Nat Med 1998, 4:50-57.
43. Walden PD, Ittmann M, Monaco ME, Lepor H: Endothelin-1 production and agonist activities in cultured prostate-derived cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. Prostate 1998, 34:241-250.
44. Nelson JB, Lee WH, Nguyen SH, et al.: Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997, 57:35-37.
45. Carducci MA, Nelson JB, Bowling MK, et al.: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 2002, 20:2171-2180.
46. Ryan CW, Vogelzang NJ, Vokes EE, et al.: Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 2004, 10:4406-4411.
47. Zonnenberg B, Groenewegen G, Janus TJ, et al.: Phase I dose-escalation study of the safety and pharmacokinetics of atrasetan: an Endothelin receptor antagonist for refractory prostate cancer. Clin Can Res 2003, 9:2965-2972.
48. Carducci M, Padley R, Breul J, et al.: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21:679-689.
49. Carducci M, Nelson JB, Saad F, et al.: Effects of atrasentan on disease progression and biological markers in men with metastatic hormone refractory prostate cancer: Phase II study. J Clin Oncol 2004, 22:384S.
50. Vogelzang N, Nelson JB, Schulman DP, et al.: Meta-analysis of clinical trials of atrasentan 10mg in metastatic hormone-refractory prostate cancer [abstract]. Proc ASCO 2005, 24:4563.